@chaelinkim.bsky.social
📤 13
📥 19
📝 2
reposted by
Finn McQuaid
15 days ago
Our framework that informed the
@who.int
TB & climate change policy brief out now in
@lancetrespirmed.bsky.social
, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
www.thelancet.com/journals/lan...
loading . . .
Climate change and tuberculosis: an analytical framework
Climate change is likely to exacerbate a range of determinants that drive tuberculosis, the world's leading cause of death from a single infectious agent. However, tuberculosis is often neglected in w...
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00329-7/fulltext
1
22
18
reposted by
Kate LeGrand
12 months ago
Reflecting on this year’s
#TB
#UnionConf2024
and am so inspired by the brilliant minds and groundbreaking research being done to combat this global health threat. Special shoutout to the TB Modelling Group
@lshtm.bsky.social
🫁
4
21
8
When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊
doi.org/10.1371/jour...
loading . . .
Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis
The WHO recommends the bedaquiline, pretomanid, and linezolid (BPaL) regimen with the additional fluoroquinolone antibiotic moxifloxacin (BPaLM) for initial treatment of multidrug- or rifampicin-resis...
https://doi.org/10.1371/journal.pgph.0005275
26 days ago
1
12
12
you reached the end!!
feeds!
log in
